Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients
Epistemonikos ID: 4e89efdbabe214525811fc57dee195bb4f30898d
First added on: May 06, 2024